Member Info for OAPK20

Any members…..

It’ll need to be, unless something else is behind the drop.

“ The Company’s key business strategies for long-term growth and profitability continue to be geographic expansion, core product innovation, acquisitions and talent retention and development.”

“ Consistent with the prior year, we have operated with two segments – our Protein Sciences segment and our Diagnostics and Genomics segment – during the second quarter of fiscal 2024. Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.”

“ A key component of the Company's strategy is to augment internal growth at existing businesses with complementary acquisitions.”

CIZ with just the commercial agreement in China and Heads of terms with CorePath, currently, you have to say CIZ is nicely packaged for acquisition and the founders nicely placed to “retire”.

8 cent dividend every quarter can’t be bad or do you think it’s just because of CIZ ?

MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable February 26, 2024, to all common shareholders of record on February 12, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

“ 10. BioTechne will buy Cizzle at a premium in Q3 2024, having satisfied themselves about the efficacy of the test.”

That would be nice. Hope he’s correct 😬

Spamming this board with VELA posts is just a way to disrupt the BB because they can’t get away with the same garbage they post on ADVFN boards because LSE site doesn’t let them away with the same garbage.

Shame they let posters change names to continue spamming though.

“ think the drawdown facility will be used first to give 6-12months runway to get CIZ test approved”

Bron still think the drawdown facility will be used first to give 6-12months runway to get CIZ test approved and then CIZ board will have fingers crossed for CDT to recover on them getting trial away for AZD asset, then CIZ can cash in for closer to Put option valuation.

No wonder PIPE holders took their $0.33cent per share profit when exercising g their right to take their money out. Emptied the CDT coffers.

“ We have incurred net losses since our inception. Our net losses were $2.3 million for the nine months ended September, 2023 and $4.9 million for Old Conduit for the year ended December 31, 2022. As of September 30, 2023, we had an accumulated deficit of $13.1 million. We do not expect to generate any significant revenues, if any, until we successfully complete adequate development of our first clinical asset. As of the date of this prospectus, our clinical assets are still in development and have not been approved by the FDA or any other regulatory body.

We have not yet demonstrated our ability to generate revenue, and we may never be able to produce revenues or operate on a profitable basis. We expect to experience operating losses and negative cash flow for the foreseeable future. Even if we are able to commercialize our technology, which may include licensing, we may never recover our research and development expenses.”

I’m here for the CIZ1b biomarker LDT and future developments or buyout.

10:08:24 - 99,999 trade at 2.21.

Wonder if the mythical 1 trade will appear in the future

😁

85% and above would be decent at Stage 1.

90-95% would be ideal.

But at 95-98% for the CIZ1b LDT detecting lung cancer at stage 1, nothing comes close to touching that.

Not first but best with Breast cancer test being developed and if that is anywhere near 95% at stage 1 too then the number of lives saved will be enormous.

That’s part of the issue though Neil. Who or what are we waiting on. Last real update re mAbs was 5th July 2022. Nothing material since. Tweets saying “developing” or “creating” etc aren’t helping.

Is FairJourney Biologics CIZ are waiting on to produce additional mAbs for new uses?

“mAb supplier agreements extended to increase use case diversity

Work initiated to extend use case to breast cancer”

Or have FJB done their bit for the CIZ1b LDT and it’s over to TECH and CorePath to confirm assay optimisation?

“Monoclonal antibody ("mAb") to CIZ1B now in assay optimisation

mAb reporter protein developed and ready for test development “

There has to have been progress which is relevant to where CIZ currently are. In the bright side money isn't being wasted issuing RNS releases.

Looks like end of April for results ended December 2023 for anything. Unless there is the possibility of Options coming into play.

When’s the next flying lesson ?

Dr. Tapolczay is scheduled to present on Wednesday, February 14, 2024, at 8:00 am EST/13:30 GMT, and will be participating in one-on-one investor meetings throughout the conference.

A live webcast of the presentation will be available on the Company Events section of the company's website at conduitpharma.com. A webcast replay can be accessed on the website and will remain available for 90 days.

VV - subtle change in language “creating” not “developing” and “ will be cost-effective”

Remains to be seen if any larger LR trades appear after close after the tweet given nearly all show as sells today.

1/2- In a report from @LungAmbition, titled: ‘Lung Cancer Screening: The Cost of Inaction, states that:

“Early detection represents the best chance to reduce the number of lives lost to lung cancer.”

#CancerDetection #LungCancer #SaveLives #NHS

2/2 - We are dedicated in our pursuit to advance early lung #cancer detection. We are creating a simple blood test that can detect the CIZ1B biomarker, which is highly associated with early-stage lung cancer. The tests will be cost-effective to produce and simple to use.

#CIZ

Best sell up and move on then. Put it towards flying lessons.

If 75% QoQ growth holds into Q4 then around 102,000 prescriptions. Tall order though. Fingers crossed it’s achieved.

Tech - yes. Called the cresta run for good reason.

Tech you should try the cresta run from the Green Welly stop if you like a driving experience.